The utilisation period of SynAct Pharma AB’s (”SynAct”) series TO 1 subscription options, which were issued in connection with the company’s listing issue in May/June 2016, is currently ongoing. The last day of trading with series TO 1 subscription options on Aktietorget is 21 March 2017 and the utilisation period ends on 23 March 2017. The holder of series TO 1 subscription options has the right to subscribe to one new share SynAct at a rate of SEK 6.40 SEK per share for each subscription option held.
Subscription with the support of series TO 1 subscription options may take place until 23 March 2017 and this shall be by simultaneous cash payment no later than 15.00. The conversion of interim shares into shares is expected to take place during Week 16, 2017.
Note that the last day of trading series TO 1 subscription options on Aktietorget is 21 March 2017.
For more information about series TO 1 subscription options, see teaser and application form available on SynAct’s (www.synactpharma.se), AktieTorget’s (www.aktietorget.se) and Sedermera Fondkommission’s (www.sedermera.se) websites respectively.
For questions regarding series TO 1 subscription options, please contact:
Sedermera Fondkommission
Tel: +46 40-615 14 10
E-mail: [email protected]
For further information about SynAct Pharma AB, please contact:
Jeppe Øvlesen Henrik Stage
CEO, SynAct Pharma AB CFO, SynAct Pharma AB
Telephone: +45 28 44 75 67 Telephone: +45 40 26 09 00
E-mail: [email protected] E-mail: [email protected]